002932 Wuhan Easy Diagnosis Biomedicine
WatchlistWuhan Easy Diagnosis Biomedicine News
Mingde Biotech (002932.SZ) released its first three quarter results, net profit of 145 million yuan, a decrease of 96.21%
Mingde Biotech (002932.SZ) released its report for the third quarter of 2023, achieving revenue of 6.2 in the first three quarters...
Mingde Biotech (002932.SZ): The company has no hospital business
On October 27, Gelonghui Biotech (002932.SZ) stated on the investor interactive platform that the company has no hospital business; the company's products related to testing for mycoplasma pneumonia are being registered.
Mingde Biotech (002932.SZ): Shareholders have not yet carried out equity pledge business
Glonghui, Oct. 20 | Matilda Biotech (002932.SZ) said on the investor interactive platform that up to now, the company's controlling shareholders, actual controllers, and senior directors and supervisors of the company have not carried out equity pledge business.
[Instant Analysis of BT Financial Report] Matilda Biotech 2023 Interim Report: Net profit declined, R&D investment continued to increase
Mingde Biotech (stock code: 002932) is a company focusing on the R&D, production, sales and service of in vitro diagnostic reagents and diagnostic instruments. The company has developed into a leading provider of comprehensive in vitro diagnostic solutions in China. However, according to its 2023 interim report, the company's financial position appears to have fluctuated somewhat. First, in terms of net assets, the company's net assets fell from 6.772 billion yuan at the end of the previous year to 6.347 billion yuan at the end of the reporting period. This is probably due to the fact that the company's total assets also declined during the same period, from 9.191 billion yuan to 7.976 billion yuan, a decrease of 13
Mingde Biotech (002932.SZ): Up to now, the product has not been connected to or collaborated with AI big models
Glonghui, Oct. 13丨Matilda Biotech (002932.SZ) said on the investor interactive platform that in the future, the company will actively lay out a combination of artificial intelligence (AI) and existing business. Up to now, the company's products have not been connected to or cooperated with AI big models.
Mingde Biotech (002932.SZ) participated in private equity investment funds focusing on two strategic emerging industry clusters: “Optical Core Screen-end Network” and Life and Health
Mingde Biotech (002932.SZ) announced that the company, Wuhan Dongke Chuangxing Venture Capital Management Co., Ltd. and Wuhan products...
Mingde Biotech (002932.SZ) invested 10 million yuan to participate in private equity investment funds
Glonghui, October 9, 丨 Mingde Biotech (002932.SZ) announced that on October 7, 2023, the company and Wuhan Dongke Innovation Star Venture Capital Management Co., Ltd., Wuhan Industrial Development Fund Co., Ltd. (hereinafter referred to as “Wuhan Fund”), Wuhan Dongke Star Power Private Equity Venture Capital Partnership (Limited Partnership), Xiong Xuan, and Xiao Jie jointly signed the “Wuhan Dongke Jucai Venture Capital Partnership (Limited Partnership) Partnership Agreement” (hereinafter referred to as “partnership agreement”) to participate in the limited investment fund Wuhan Dongke Gucai Venture Investment Partnership (Limited Partnership) (“Partnership Agreement”). Partnership) (hereinafter referred to as “Foundation”
Matilda Biotech (002932.SZ): 1,940,400 restricted stocks will be unbanned on October 9
Glonghui, September 26丨Mingde Biotech (002932.SZ) announced an indicative announcement on the 2019 Restricted Stock Incentive Plan for the first time, the third unlocking period for restricted stocks, the third unlocking period to lift the sale restrictions, and the listing and circulation of restricted shares. The number of restricted shares lifted this time was 1,904,414 million shares, accounting for about 0.8345% of the company's current total share capital of 232,520,957 shares. The number of people applying for the lifting of sales restrictions is 52. The listing and circulation date of the lifted shares is October 9, 2023 (Monday).
Matilda Biotech (002932.SZ): Net profit for the first half of the year fell 95.92% to 113 million yuan
GLONGHUI, August 30 | Mingde Biotech (002932.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 538 million yuan, down 89.77% year on year; net profit attributable to shareholders of listed companies was 113 million yuan, down 95.92% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 35.031 million yuan, down 98.73% year on year; basic earnings per share were 0.49 yuan.
Matilda Biotech (002932.SZ): Regular business development in the third quarter was good, and orders were stable
GLONGHUI, August 28丨Some investors asked Mingde Biotech (002932.SZ), “How was the company's regular business in the third quarter? Is the order stable?” Mingde Biotech replied that the company's regular business development in the third quarter was good and orders were stable!
Mingde Biotech (002932.SZ): The current market value is seriously underestimated. The actual controller is firmly optimistic about the company's future long-term development, and there are no plans to reduce holdings in the short term
GLONGHUI, August 28丨Some investors asked Mingde Biotech (002932.SZ), “According to the latest regulations, has the company's stock price gone bankrupt, and none of the actual controllers of the majority shareholders can reduce their holdings?” Mingde Biotech replied that according to the “Securities Regulatory Commission Further Regulates Share Holdings Reduction” notice on August 27, the company's current market value is lower than the latest period of net assets attributable to shareholders of the parent company disclosed by the company (6.587 billion yuan), and the closing price of the last trading day is lower than the disclosed net assets per share (28.32 yuan) of the latest issue (28.32 yuan), so controlling shareholders and actual controllers are not allowed to reduce their holdings of the company's shares through the secondary market. Public
Mingde Biotech (002932.SZ): AI technology has been applied to related products that have been commercialized by Boyin Hearing, and is currently in a leading position in China
Glonghui, August 28丨An investor asked Mingde Biotech (002932.SZ), “The “Boyin Hearing” invested by your company claims to be a national high-tech enterprise focusing on the development of “AI Intelligent Hearing Aids+Hearing Expert Center” integrating design, development, production and sales. As of October 2022, Boyin Listening has obtained 11 national patents and 22 software copyrights. May I ask if Boyin Hearing's AI smart hearing aids have mature technology and products, are they real AI or just a fun concept, please answer positively.” Matilda Biotech replied, “In August 2023, a fund managed by Ming Xi Venture Capital, a subsidiary of the company, said
Mingde Biology (002932.SZ): The immunization product line can provide detection reagents for tumor markers, thyroid function, cardiovascular and cerebrovascular diseases, and eugenics
GLONGHUI, August 28丨An investor asked Matilda Biotech (002932.SZ), “May I ask if Japan's nuclear pollution drains the ocean. Does your company have diagnostic products or equipment for diseases related to nuclear pollution?” Mingde Biotech replied that Japan's nuclear pollution discharge contains a large amount of radioactive isotopes, which may cause a sharp rise in the incidence of cancers such as thyroid cancer, lung cancer, and liver cancer, and may also affect human fertility or cause neurological diseases. In response to the multiple diseases described above, the company's immunization product line can provide detection reagents for tumor markers, thyroid function, cardiovascular and cerebrovascular diseases, eugenics, etc. The company is under the jurisdiction of Ming Zhi Medical
Matilda Biotech (002932.SZ): The current market value is lower than the net assets of Huimu; the company's market value is seriously underestimated
GLONGHUI July 18丨Some investors asked Mingde Biotech (002932.SZ), “What is your company's net market ratio as of July 17? Has the stock price fallen below net worth? Combined with industry averages, what range do you think the company's reasonable market value is currently in?” In response, Mingde Biotech said that according to the company's net asset estimates disclosed at the end of the first quarter, the company's current market value is lower than that of Gimu's net assets. The company's net assets are mainly composed of highly liquid assets such as cash and time deposits. The company's fixed assets and intangible assets are mainly factory buildings and land in the Donghu High-tech Zone in Wuhan City. The company's current market value is already
Matilda Biotech (002932.SZ): Net profit is expected to drop 95.29%-96.38% year-on-year in the first half of the year
On July 13, GLONGHUI (002932.SZ) announced that net profit for the first half of the year is expected to be 10,000 million yuan to 130 million yuan, down 96.38% to 95.29% from the same period last year, after deducting non-net profit of 30 million yuan to 40 million yuan, down 98.91% to 98.55% from the same period last year. In the first half of 2023, China's economic and social life gradually returned to normal, and market demand for epidemic prevention testing products dropped sharply, which led to a sharp decline in the company's profits in the first half of 2023.
Mingde Biotech: 150 million yuan to participate in private equity investment funds
Gelonghui, June 25丨Mingde Biotech announced that on the same day, the company signed partnership agreements with Chengdu Junqi Enterprise Management Consulting Partnership (Limited Partnership), Chengdu High-tech Ceyuan Sailing Equity Investment Fund Partnership (Limited Partnership), Bozhou Kangan Investment Fund Co., Ltd., Jiankai Technology, Anhui Yingjia Investment Management Co., Ltd., Cory Technology, etc. to participate in the investment fund Chengdu Junrongkang Venture Capital Partnership (limited partnership). The fund size is 1.6 billion yuan, of which the company invested 150 million yuan as a limited partner and held 9.38% of the shares; Jiankai Technology and Cory Technology each invested 500 as limited partners
Mingde Biotech (002932.SZ): Intended to participate in Chengdu Junrongkang's venture capital partnership focusing on innovative drugs and biotechnology, medical devices and diagnostic technology
Gelonghui, June 25, 丨 Mingde Biotech (002932.SZ) announced that on June 25, 2023, the company and Chengdu Junqi Enterprise Management Consulting Partnership (Limited Partnership) (“Chengdu Junqi”), Chengdu Hi-Tech Ceyuan Sailing Equity Investment Fund Partnership (limited partnership), Tibet Joint Investment Enterprise Enterprise Management Co., Ltd., Suzhou Junlian Jinghui Venture Capital Partnership (limited partnership), Pingtan Jianfa No. 3 Equity Investment Partnership (limited partnership), Bozhou Kangan Investment Fund, Chengdu Biotech Co., Ltd. Venture Equity Investment Fund Partnership (Limited) partnership), Suzhou Junlian Rui Sichuang
Mingde Biotech (002932.SZ) plans to invest 150 million yuan in private equity funds to focus on innovative drugs and biotechnology
According to the Zhitong Finance App, Mingde Biotech (002932.SZ) issued an announcement. On June 25, 2023, the company and Chengdu Junqi Enterprise Management Consulting Partnership (Limited Partnership) jointly signed the “Chengdu Junrongkang Venture Capital Partnership Limited Partnership Agreement” to participate in the investment fund Chengdu Junrongkang Venture Capital Partnership (Limited Partnership). The size of the fund is 1.6 billion yuan, and the company invested 150 million yuan as a limited partner, with a shareholding ratio of 9.38%. The fund focuses on innovative drugs and biotechnology, medical devices and diagnostic technology, professional services and supply chains, with a focus on early innovation and the local supply chain
Mingde Biotech (002932.SZ) plans to invest 175 million yuan in investment funds to find investment opportunities in the healthcare sector
According to the Zhitong Finance App, Mingde Biotech (002932.SZ) announced that on June 20, 2023, the company and Mingxi Venture Capital Management (Wuhan) Co., Ltd. (“Mingxi Venture Capital”), Ms. Chen Lili, and Lhasa Qijun Enterprise Management Co., Ltd. jointly signed the “Wuhan Mingjun Hezong Venture Capital Fund Partnership (Limited Partnership)” in Wuhan City, Hubei Province to participate in the investment fund Wuhan Mingjun Joint Venture Capital Fund Partnership (Limited Partnership) (limited partnership) (limited partnership) to participate in the investment fund. The size of the fund is RMB 235 million, of which Myung Hee Venture Capital is an ordinary partner
Mingde Biotech (002932.SZ): Intended to participate in a private equity investment fund that mainly engages in venture capital activities for companies in the healthcare sector
Gelonghui, June 20, 丨 Mingde Biotech (002932.SZ) announced that on June 20, 2023, Wuhan Mingde Biotechnology Co., Ltd., Mingxi Venture Capital Management (Wuhan) Co., Ltd. (“Mingxi Venture Capital”), Ms. Chen Lili, and Lhasa Junqi Enterprise Management Co., Ltd. jointly signed the “Wuhan Mingjun Joint Venture Capital Fund Partnership (Limited Partnership)” in Wuhan City, Hubei Province. Participating in the investment fund, Wuhan Mingjun Joint Venture Capital Fund Partnership (Limited Partnership) (Limited Partnership) (the specific name is subject to the filing) Abbreviated as “fund” or “limited partnership”). base